Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
675 articles
A formula using standard lipid panels estimates small, dense LDL and outperforms LDL-C and rivals ApoB in predicting ASCVD risk across 271,760 adults.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
A forward genetic screen in mice reveals HELZ2 helicase degrades APOB mRNA, linking RNA stability to fatty liver disease and heart disease risk.
Not all fibrates work the same way — fenofibrate uniquely reduces apoB, cutting residual cardiovascular risk beyond statins alone.
A new PET imaging metric identifies patients with normal scans who still face 41% higher cardiovascular event risk.
A newly identified molecular glitch in MAML1 phase separation disrupts Notch signaling and causes ventricular septal defects.
A simulation of 250,000 adults finds using apoB goals to guide lipid-lowering therapy costs just $30,300 per QALY gained vs. non-HDL-C, making it highly cost-effective.
Even with optimal LDL control, remnant cholesterol, Lp(a), and apoB drive ongoing ASCVD risk — and new therapies are emerging to address them.
Ongericimab slashed LDL cholesterol by over 66% vs placebo in a phase 3 trial, offering a promising option for patients who can't tolerate statins.
A new analysis shows olezarsen reduces apoC-III by up to 75% across chylomicrons, HDL, LDL/VLDL, and Lp(a) in familial chylomicronemia syndrome.
Genetic modeling shows RNA interference and antibody-based PCSK9 inhibitors deliver equivalent cardiovascular benefits when matched for apoB reduction.
A distinct immune remodeling process — separate from classical immunosenescence — predicts arterial stiffness with surprising accuracy.
